Sihuan Pharmaceutical (0460) Announces Proposed H Share Full Circulation for Xuanzhu Biopharma (2575)

Bulletin Express11-18

Sihuan Pharmaceutical (0460) announced that its subsidiary, Xuanzhu Biopharma (2575), is proceeding with a proposal for H share full circulation. According to announcements dated 14 November 2025 and 17 November 2025, Xuanzhu Biopharma has submitted an application to the China Securities Regulatory Commission on 17 November 2025 for the conversion of 357,245,794 unlisted shares held by six shareholders into H shares on a one-to-one basis. These shares represent approximately 68.9733% of Xuanzhu Biopharma’s total issued shares as of 14 November 2025.

As of the date of the announcement, Xuanzhu Biopharma has not applied to the Stock Exchange for the listing of these converted shares, and relevant details of the circulation plan have yet to be finalized. The company has indicated that further announcements regarding any progress or updates will be made in due course.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169932779?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169932779","market":"us","top_or_hot":-1,"title":"Sihuan Pharmaceutical (0460) Announces Proposed H Share Full Circulation for Xuanzhu Biopharma (2575)","media":"Bulletin Express","content":"<p>Sihuan Pharmaceutical (0460) announced that its subsidiary, Xuanzhu Biopharma (2575), is proceeding with a proposal for H share full circulation. According to announcements dated 14 November 2025 and 17 November 2025, Xuanzhu Biopharma has submitted an application to the China Securities Regulatory Commission on 17 November 2025 for the conversion of 357,245,794 unlisted shares held by six shareholders into H shares on a one-to-one basis. These shares represent approximately 68.9733% of Xuanzhu Biopharma’s total issued shares as of 14 November 2025.</p>\n<p>As of the date of the announcement, Xuanzhu Biopharma has not applied to the Stock Exchange for the listing of these converted shares, and relevant details of the circulation plan have yet to be finalized. The company has indicated that further announcements regarding any progress or updates will be made in due course.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharmaceutical (0460) Announces Proposed H Share Full Circulation for Xuanzhu Biopharma (2575)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharmaceutical (0460) Announces Proposed H Share Full Circulation for Xuanzhu Biopharma (2575)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-18 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sihuan Pharmaceutical (0460) announced that its subsidiary, Xuanzhu Biopharma (2575), is proceeding with a proposal for H share full circulation. According to announcements dated 14 November 2025 and 17 November 2025, Xuanzhu Biopharma has submitted an application to the China Securities Regulatory Commission on 17 November 2025 for the conversion of 357,245,794 unlisted shares held by six shareholders into H shares on a one-to-one basis. These shares represent approximately 68.9733% of Xuanzhu Biopharma’s total issued shares as of 14 November 2025.</p>\n<p>As of the date of the announcement, Xuanzhu Biopharma has not applied to the Stock Exchange for the listing of these converted shares, and relevant details of the circulation plan have yet to be finalized. The company has indicated that further announcements regarding any progress or updates will be made in due course.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"","article_id":"1169932779","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169932779","pubTimestamp":1763479293,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sihuan Pharmaceutical (0460) announced that its subsidiary, Xuanzhu Biopharma (2575), is proceeding with a proposal for H share full circulation. According to announcements dated 14 November 2025 and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00460":"四环医药"},"translate_title":"四环医药(0460)公布拟H股全流通轩竹生物(2575)","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"Sihuan Pharmaceutical (0460) announced that its subsidiary, Xuanzhu Biopharma (2575), is proceeding with a proposal for H share full circulation. According to announcements dated 14 November 2025 and 17 November 2025, Xuanzhu Biopharma has submitted an application to the China Securities Regulatory Commission on 17 November 2025 for the conversion of 357,245,794 unlisted shares held by six shareholders into H shares on a one-to-one basis. These shares represent approximately 68.9733% of Xuanzhu Biopharma’s total issued shares as of 14 November 2025.\nAs of the date of the announcement, Xuanzhu Biopharma has not applied to the Stock Exchange for the listing of these converted shares, and relevant details of the circulation plan have yet to be finalized. The company has indicated that further announcements regarding any progress or updates will be made in due course.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169932779","isCrawlerRequest":true}